



- (51) **International Patent Classification:**
A61K 38/16 (2006.01) *A61P 25/00* (2006.01)
- (21) **International Application Number:**
PCT/CN2015/092299
- (22) **International Filing Date:**
20 October 2015 (20.10.2015)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/065,884 20 October 2014 (20.10.2014) US
- (71) **Applicant:** MYCOMAGIC BIOTECHNOLOGY CO., LTD [CN/CN]; 8F-1, No. 12, Lane 270, Sec. 3, Beishen Rd., Shengkeng Dist., New Taipei City, Taiwan 222 (CN).
- (72) **Inventor:** CHAO, Ming-Wei; No. 200, Chung-pei Rd., Chung-li City, Taoyuan, Taiwan 320 (CN).
- (74) **Agent:** LEE AND LI - LEAVEN IPR AGENCY LTD.; Unit 2202, Tower A, Beijing Marriott Center, No. 7, Jian Guo Men South Avenue, Beijing 100005 (CN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** NEW USE OF IMMUNOMODULATORY PROTEIN FROM *GANODERMA* IN PROMOTING NEURITE OUT-GROWTH




Fig. 1

(57) **Abstract:** A method for promoting neurite outgrowth is provided by the invention, and the method comprises exposing the neurons to an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof. A method for treating and/or preventing a neurological disorder is also provided, and the method comprises administering an effective amount of an immunomodulatory protein derived from Ganoderma, or a recombinant or a composition thereof to a subject.



NEW USE OF IMMUNOMODULATORY PROTEIN FROM *GANODERMA* IN PROMOTING NEURITE OUTGROWTH

Field of the Invention

[0001] The present invention relates to a new use of an immunomodulatory protein
5 derived from *Ganoderma* or a recombinant or a composition thereof in promoting neurite
outgrowth and treating and/or preventing neurological disorders. Particularly, the
immunomodulatory protein is derived from *Ganoderma microsporum*.

Background of the Invention

[0002] Once a neural circuit network is damaged by brain injury or spinal cord injury and
10 the network is thereby cut off or results in nerve cell death, the physiological and/or motor
functions governed by nerves are lost, and it becomes extremely difficult to restore the neural
circuit. Neurites are often packed with microtubule bundles, the growth of which is stimulated
by Nerve Growth Factor (NGF), as well as tau proteins, MAP1, and MAP2. US 6,207,639
provides methods for enhancing and/or directing neurite outgrowth, comprising contacting a
15 neuron with a cell adhesion modulating agent, wherein the modulating agent enhances cadherin-
mediated cell adhesion. US 7,846,438 discloses contacting a neuron (such as a CNS neuron)
with an effective amount of an agent that modulates TAJ complex formation and/or signaling to
modulate growth and/or survival of a neuron. US 8,481,711 provides a non-peptidic nerve axon
and/or neurite outgrowth agent for allowing a nerve axon and a neurite to elongate.

[0003] Many therapeutic effects have been reported of Lingzhi species, such as
20 immunomodulatory, anti-tumor, hepato-protective, antioxidant, and cholesterol-lowering effects
(Jinn *et al.*, 2006, *Biosci Biotechnol Biochem*, 70, 2627-2634). All of these therapeutic effects
are attributed to triterpenoids, polysaccharides, and glycoproteins (Boh *et al.*, 2007, *Biotechnol
Annu Rev*, 13, 265-301; Jinn *et al.*, 2006, *Biosci Biotechnol Biochem*, 70, 2627-2634). A new
25 glycoprotein class in Lingzhi named fungal immunomodulatory proteins (FIPs) was recently
identified. So far, at least 4 FIPs have been isolated and purified from *Ganoderma lucidum*, LZ-
8, (*G. lucidum*), FIP-gts (*Ganoderma tsugae*), and FIP-gja (*Ganoderma sinensis*) (Hsu *et al.*,
1997, *Biochem J*, 323 (Pt 2), 557-565; Ko *et al.*, 1995, *Eur J Biochem*, 228, 244-249; Xuanwei
et al., 2008, *Planta Med*, 74, 197-200). According to a previous study, FIP-gts from *G. tsugae*, a
30 popular chemopreventive mushroom in Asia, has anti-cancer function and is involved in the
regulation of hTERT/telomerase expression (Liao *et al.*, 2006, *Mol Carcinog*, 45, 220-229). In

addition, FIP-gts inhibits the growth of A549 cancer cells, leading to cell cycle arrest, consequently inducing premature cellular senescence in lung cancer cells. Moreover, FIP-gts results in significant inhibition of tumor growth in athymic nude mice implanted with A549 cells (*Liao et al., 2008, Food Chem Toxicol, 46, 1851-1859*). US 20100009915 provides a method for suppressing proliferation of a cancer cell and a method for suppressing a tumor cell mobility, comprising providing to the tumor cell a purified polypeptide of a fungal immunomodulatory protein, LZ-8. US 7,601,808 discloses an immunomodulatory protein cloned from *Ganoderma microsporum* and this protein has immunomodulator efficiency.

[0004] However, no prior art discloses, teaches or suggests that immunomodulatory proteins from *Ganoderma* are relevant to neurite outgrowth.

Summary of the Invention

[0005] The invention provides a method for promoting neurite outgrowth, the method comprising exposing the neuron to an effective amount of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof, thereby promoting neurite outgrowth. Particularly, the immunomodulatory protein from *Ganoderma*, or a recombinant thereof can promote the outgrowth of axons and dendrites.

[0006] The invention also provides a use of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof, for the manufacture of a medicament for promoting neurite outgrowth.

[0007] The invention also provides a method for treating and/or preventing a neurological disorder, the method comprising administering an effective amount of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof to a subject thereby treating and/or preventing a neurological disorder.

[0008] The invention also provides a use of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof for the manufacture of a medicament for treating and/or preventing a neurological disorder.

[0009] In one embodiment, the immunomodulatory protein is derived from *Ganoderma lucidum*, *Ganoderma lucidum*, *Ganoderma tsugae*, *Ganoderma microsporum* or *Ganoderma sinensis*. Preferably, the immunomodulatory protein is LZ-8 derived from *Ganoderma lucidum*, FIP-gts derived from *Ganoderma tsugae*, GMI derived from *Ganoderma microsporum*, or FIP-gja derived from *Ganoderma sinensis* or a recombinant thereof. Preferably, the

immunomodulatory protein is derived from *Ganoderma microsporum* (GMI) or a recombinant thereof (reGMI). More preferably, the reGMI has the amino acid sequence as shown in SEQ ID NO: 1 and SEQ ID NO: 2, SEQ ID NO:3 or SEQ ID NO:4.

[0010] In one embodiment, the immunomodulatory protein from *Ganoderma*, or a recombinant or a composition thereof are therefore useful in the therapy of, for example, disorders of the nervous system, conditions of the nervous system that are secondary to a disease, condition, or therapy having a primary effect outside of the nervous system, injuries to the nervous system caused by physical, mechanical, or chemical trauma, memory loss, or psychiatric disorders. In another embodiment, the method of the invention can be used in the treatment of peripheral nerve damage caused by physical injury (associated with, e.g., burns, wounds, surgery, and accidents), ischemia, prolonged exposure to cold temperature (e.g., frost-bite), damage to the central nervous system due to, for example, stroke or intracranial hemorrhage (such as cerebral hemorrhage), dementia, Alzheimer's disease, Huntington's disease or Parkinson's disease.

[0011] In another embodiment, immunomodulatory protein from *Ganoderma*, or a recombinant thereof can be combined with a neurite outgrowth agent for combination therapy in promoting neurite outgrowth or treating and/or preventing a neurological disorder.

Brief Description of the Drawing

[0012] Figure 1 shows the treatment with recomGMI in different concentration and scrape at immature neurons (Group 1: Treat and scrape at same time).

[0013] Figure 2 shows the treatment with recomGMI in different concentration at DIV8 and scrape at immature neurons (Group 2: PreTreat 48 h and scrape later).

[0014] Figure 3 shows the treatment with recomGMI in different concentration at DIV15 and scrape at DIV17 (Group 4: PreTreat 48 h and scrape later).

[0015] Figure 4 shows that the distance of neurite outgrowth was measured after injury and recomGMI treatment. (A) Group 1: immature neuron, post-treatment; (B) Group 2: immature neuron, pre-treatment; (C) Group 3: mature neuron, post-treatment; (D) Group 4: mature neuron, pre-treatment. For statistical analysis, each experiment was performed in triplicate and repeated 3 times. The results were expressed as means \pm SD for three independent experiments, and analyzed the differences between the groups by using Student t-tests with

GraphPad statistics software. $*p < 0.05$, $**p < 0.01$ and $***p < 0.001$ compared with the controls indicate significant differences.

[0016] Figure 5 shows the animal model results of the treatment with recomGMI in Morris water maze task assay.

Detailed Description of the Invention

[0017] The invention surprisingly found that an immunomodulatory protein from *Ganoderma* can promote neurite outgrowth, suggesting that the immunomodulatory protein from *Ganoderma* can treat and/or prevent neurological disorders.

[0018] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference.

[0019] In this application, the use of the singular includes the plural, the article "a" or "an" means "at least one", and the use of "or" means "and/or", unless specifically stated otherwise.

[0020] In this application, the word "comprise," or variations such as "comprises" or "comprising," indicate the inclusion of any recited integer or group of integers but not the exclusion of any other integer or group of integers in the specified method, structure, or composition.

[0021] As used herein, the term "neuron" includes a neuron and a portion or portions thereof (e.g., the neuron cell body, an axon, or a dendrite). The term "neuron" denotes nervous system cells that include a central cell body or soma and two types of extensions or projections: dendrites, by which, in general, the majority of neuronal signals are conveyed to the cell body, and axons, by which, in general, the majority of neuronal signals are conveyed from the cell body to effector cells, such as target neurons or muscle.

[0022] The term neurite as used herein encompasses all such cell processes (including both axon and dendrite) growing out of a neuron.

[0023] The term "neurite outgrowth" refers to the process of cells growing out of a neuron, or to the cells comprising an outgrowth from a neuron.

[0024] As used herein, "neurological disorders" means any physiological dysfunction or death of neurons present in the central nervous system or peripheral nervous system or caused by glia cell dysfunction. A non-limited list of such disorders comprises multiple sclerosis, sciatic nerve defect, brain or code injury, dementia, frontotemporal lobe dementia, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion diseases, neuronopathies and motor neuron disorders. "Neuronopathies" are characterized by neuronal cell death of motor neurons or sensory neurons, and hence neuronopathies can be subdivided into motor and sensory neuron disorders.

[0025] As used herein, "promote" or "increase", or "promoting" or "increasing" are used interchangeably herein. These terms refer to the increase in a measured parameter in a treated cell (tissue or subject) in comparison to an untreated cell (tissue or subject). A comparison can also be made of the same cell or tissue or subject between before and after treatment. The increase is sufficient to be detectable. In some embodiments, the increase in the treated cell is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 1-fold, 2-fold, 3-fold, 4-fold or more in comparison to an untreated cell.

[0026] As used herein, "inhibit", "prevent" or "reduce," or "inhibiting", "preventing" or "reducing" are used interchangeably herein. These terms refer to the decrease in a measured parameter in a treated cell (tissue or subject) in comparison to an untreated cell (tissue or subject). A comparison can also be made of the same cell or tissue or subject between before and after treatment. The decrease is sufficient to be detectable. In some embodiments, the decrease in the treated cell is at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or completely inhibited in comparison to an untreated cell. In some embodiments the measured parameter is

[0027] As used herein, "treatment" or "treating" or "ameliorating" are used interchangeably herein. These terms refer to an approach for obtaining beneficial or desired results including, but not limited to, therapeutic benefit and/or a prophylactic benefit. Therapeutic benefit pertains to eradication or amelioration of the underlying disorder being treated. Also, a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding that the patient may still be afflicted with the underlying disorder. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already

with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0028] As used herein, "therapeutically effective amount" means an amount sufficient to treat a subject afflicted with a disease or to alleviate a symptom or a complication associated with the disease.

[0029] As used herein, "subject" refers to either a human or non-human animal.

[0030] In one aspect, the invention provides a method for promoting neurite outgrowth, the method comprising exposing the neuron to an effective amount of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof, thereby promoting neurite outgrowth. The immunomodulatory protein from *Ganoderma*, or a recombinant thereof of the present disclosure can be used to promote neurite outgrowth. Particularly, the immunomodulatory protein from *Ganoderma*, or a recombinant thereof can promote the outgrowth of axons and dendrites. By exposing the neurons to the effective amount of the immunomodulatory protein from *Ganoderma*, or a recombinant thereof, the axons and dendrites increase in length and density and recover by regeneration.

[0031] In one embodiment, the immunomodulatory protein or a recombinant thereof is derived from *Ganoderma lucidum*, *Ganoderma tsugae*, *Ganoderma microsporum* or *Ganoderma sinensis*. Preferably, the immunomodulatory protein is LZ-8 derived from *Ganoderma lucidum*, FIP-gts derived from *Ganoderma tsugae*, GMI derived from *Ganoderma microsporum*, or FIP-gja derived from *Ganoderma sinensis* or a recombinant thereof.

[0032] In one embodiment, the immunomodulatory protein is derived from *Ganoderma microsporum* (GMI) or a recombinant thereof (reGMI). More preferably, the immunomodulatory protein (GMI or reGMI) has the amino acid sequence: (1) -Leu-Ala-Trp-Asn-Val-Lys-(LAWN VK; SEQ ID NO:1) and (2) -Asp-Leu-Gly-Val-Arg-Pro-Ser-Tyr-Ala-Val-(DLGVRPSYAV; SEQ ID NO:2), the amino acid sequence of: MSDTALIFTLAWN VKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVV VSGKD LGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWN (SEQ ID NO:3) or the amino acid sequence of EAEAEFMSDTALIFTLAWN VKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVV VSGKDLGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWNY LEQKLISEEDLNSAVDHHHHHH (SEQ ID NO:4).

[0033] In one embodiment, the amount for promotion of neurite outgrowth ranges from about 0.65 µg to about 650 µg weight of the immunomodulatory protein per kg body weight. Amounts between about 0.65 µg to about 6.5 µg, about 6.5 µg to about 65 µg, about 65 µg to about 650 µg of the immunomodulatory protein per kg body weight are more preferred; more preferably, about 6.5 µg to about 325 µg of the immunomodulatory protein per kg body weight.

[0034] In another aspect, the invention provides a method for treating and/or preventing a neurological disorder, the method comprising administering an effective amount of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof to a subject thereby treating and/or preventing a neurological disorder. The immunomodulatory protein from *Ganoderma*, or a recombinant or a composition thereof of the present disclosure can be used to treat and/or prevent neurological disorder. The immunomodulatory protein from *Ganoderma*, or a recombinant or a composition thereof are therefore useful in the therapy of, for example, (i) disorders of the nervous system (e.g., neurodegenerative diseases), (ii) conditions of the nervous system that are secondary to a disease, condition, or therapy having a primary effect outside of the nervous system, (iii) injuries to the nervous system caused by physical, mechanical, or chemical trauma, (iv) memory loss, and (v) psychiatric disorders. Examples of neurodegenerative diseases and conditions that can be prevented or treated according to the invention include amyotrophic lateral sclerosis (ALS), trigeminal neuralgia, glossopharyngeal neuralgia, Bell's Palsy, myasthenia gravis, muscular dystrophy, progressive muscular atrophy, primary lateral sclerosis (PLS), pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy, progressive bulbar palsy, inherited muscular atrophy, invertebrate disk syndromes (e.g., herniated, ruptured, and prolapsed disk syndromes), cervical spondylosis, plexus disorders, thoracic outlet destruction syndromes, peripheral neuropathies, porphyria, mild cognitive impairment, Alzheimer's disease, Huntington's disease, Parkinson's disease, Parkinson-plus syndromes (e.g., multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration), dementia, frontotemporal dementia, demyelinating diseases (e.g., Guillain-Barre syndrome and multiple sclerosis), Charcot-Marie-Tooth disease (CMT; also known as Hereditary Motor and Sensory Neuropathy (HMSN), Hereditary Sensorimotor Neuropathy (HSMN), and Peroneal Muscular Atrophy), prion disease (e.g., Creutzfeldt-Jakob disease, Gerstmann-Straussler-Scheinker syndrome (GSS), fatal familial insomnia (FFI), and bovine spongiform encephalopathy (BSE, commonly known as mad cow disease)), Pick's disease, epilepsy, and

AIDS demential complex (also known as HIV dementia, HIV encephalopathy, and HIV-associated dementia).

[0035] In addition, the methods of the invention can be used in the treatment of nerve damage, such as peripheral neuropathy. The methods of the invention can also be used to treat injury to the nervous system caused by physical, mechanical, or chemical trauma. Thus, the methods can be used in the treatment of peripheral nerve damage caused by physical injury (associated with, e.g., burns, wounds, surgery, and accidents), ischemia, prolonged exposure to cold temperature (e.g., frost-bite), as well as damage to the central nervous system due to, for example, stroke or intracranial hemorrhage (such as cerebral hemorrhage).

[0036] In one embodiment, the immunomodulatory protein or a recombinant thereof is derived from *Ganoderma lucidum*, *Ganoderma lucidum*, *Ganoderma tsugae*, *Ganoderma microsporum* or *Ganoderma sinensis*. Preferably, the immunomodulatory protein is LZ-8 derived from *Ganoderma lucidum*, FIP-gts derived from *Ganoderma tsugae*, GMI derived from *Ganoderma microsporum*, or FIP-gja derived from *Ganoderma sinensis* or a recombinant thereof.

[0037] In one embodiment, the immunomodulatory protein is derived from *Ganoderma microsporum* (GMI) or a recombinant thereof (reGMI). More preferably, the immunomodulatory protein (GMI or reGMI) has the amino acid sequence: (1) -Leu-Ala-Trp-Asn-Val-Lys-(LAWN VK; SEQ ID NO:1) and (2) -Asp-Leu-Gly-Val-Arg-Pro-Ser-Tyr-Ala-Val-(DLGVRPSYAV; SEQ ID NO:2), the amino acid sequence of: MSDTALIFTLAWN VKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVV VSGKDLGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWN (SEQ ID NO:3), or the amino acid sequence of EAEAEFMSDTALIFTLAWN VKQLAFDYTPNWGRGRPSSFIDTVTFPTVLTDKAYTYRVV VSGKDLGVRPSYAVESDGSQKINFLEYNSGYGIADTNTIQVYVIDPDTGNNFIVAQWNY LEQKLISEEDLNSAVDHHHHHH (SEQ ID NO:4).

[0038] The immunomodulatory protein or a recombination thereof of the invention can be administered to a patient either alone or in pharmaceutical compositions where it is mixed with suitable carriers and excipients. The immunomodulatory protein or a recombination thereof or a composition of the invention can be administered parenterally, such as by intravenous injection or infusion, intraperitoneal injection, subcutaneous injection, or intramuscular injection. The immunomodulatory protein or a recombination thereof or a composition can be administered

orally or rectally through appropriate formulation with carriers and excipients to form tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like. The immunomodulatory protein or a recombination thereof or a composition can be administered topically, such as by skin patch. The immunomodulatory protein or a recombination thereof or a composition can be formulated into topical creams, skin or mucosal patch, liquids or gels suitable to topical application to skin or mucosal membrane surfaces. The immunomodulatory protein or a recombination thereof or a composition can be administered by inhaler to the respiratory tract for local or systemic treatment of cancers.

[0039] In one embodiment, the amount of the immunomodulatory protein or a recombination thereof for administration may range from about 0.65 μg to about 650 μg weight of the immunomodulatory protein per kg body weight. Amounts between about 0.65 μg to about 6.5 μg , about 6.5 μg to about 65 μg , about 65 μg to about 650 μg of the immunomodulatory protein per kg body weight are more preferred; more preferably, about 6.5 μg to about 325 μg of the immunomodulatory protein per kg body weight.

[0040] The dosage of the immunomodulatory protein or a recombination thereof or a composition suitable for use according to the present invention can be determined by those skilled in the art on the basis of the disclosure herein. The medicament will contain an effective dosage (depending upon the route of administration and pharmacokinetics of the active agent) of suitable pharmaceutical carriers and excipients are suitable for the particular route of administration of the formulation (i.e., oral, parenteral, topical or by inhalation). The immunomodulatory protein or a recombination thereof is mixed into the pharmaceutical composition by means of mixing, dissolving, granulating, dragee-making, emulsifying, encapsulating, entrapping or lyophilizing processes. The pharmaceutical compositions for parenteral administration include aqueous solutions of the inventive polypeptide in water-soluble form. Additionally, suspensions of the inventive polypeptide may be prepared as oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. The suspension may optionally contain stabilizers or agents to increase the solubility of the complex or combination to allow for more concentrated solutions.

[0041] In another embodiment, the immunomodulatory protein or a recombination thereof can be combined with a neurite outgrowth agent for combination therapy in promoting neurite outgrowth or treating and/or preventing a neurological disorder. The immunomodulatory protein a recombinant thereof also can be combined with a neurite outgrowth agent as a pharmaceutical composition. That is, the invention provides a pharmaceutical composition comprising the immunomodulatory protein or a recombinant thereof and an additional neurite outgrowth agent and the composition can promote neurite outgrowth or treat and/or prevent a neurological disorder. In one embodiment, the neurite outgrowth agent is a nicotinamide adenine dinucleotide (NAD) analogue; a neurotrophic factor containing a 5-acyl-2-amino-1,3-selenazole analogue; a neurotrophic factor containing ebselen; a neurite outgrowth agent containing at least one compound selected from the group consisting of caffeic acid and a derivative thereof; a neurite outgrowth agent containing at least one plant extract selected from the group consisting of rosemary and sage that contain carnosic acid; a cell death suppressing substance containing lysophosphatidylethanolamine; a neurite outgrowth composition containing a cell organelle alkalinization agent such as monensin or concanamycin A; a neurite outgrowth agent containing polyalkoxyflavonoid such as nobiletin or tangeretin; a neurite outgrowth activator containing a glycosaminoglycan derivative; a neurite outgrowth agent containing a lactacystin derivative; a neurite outgrowth agent containing a small molecule heterocyclic ketone or thioester compound; a neurite outgrowth agent containing derivatives of ganglioside and N-acyl-N-lyso-ganglioside, N'-acyl-N'-lyso-ganglioside, and N,N'-di- or poly-acyl-N,N'-dilyso-ganglioside; a neurite outgrowth agent comprising a chondroitin sulfate/dermatan sulfate hybrid chain containing a disaccharide of GlcUA(2S)-GalNAc(4S) (B unit); a neurite outgrowth inducer containing a sugar chain having a bisecting GlcNAc, a complex carbohydrate having the aforementioned sugar chain in the structure thereof, a derivative of the aforementioned sugar chain, etc.; a neurite outgrowth inducer containing, as an active ingredient, a low-molecular-weight synthetic compound; Tctex-1-related polypeptide; TAJ polypeptide; or neural cell adhesion molecule.

[0042] Without further elaboration, it is believed that one skilled in the art can utilize the present invention to its fullest extent on the basis of the preceding description. The following examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

Example

Example 1 Neurite Regeneration Assay

[0043] The recombinant immunomodulatory protein derived from *Ganoderma microsporum* (hereafter referred to as “recomGMI”) was manufactured by Mycomagic Biotechnology Co., Ltd., according to the method described in US 7,601,808 and has an amino acid sequence shown in Fig. 3B of US 7,601,808.

[0044] Neuronal cultures were prepared from hippocampi or cortices of rat embryos of both sexes at 18 days of gestation as described previously (*Firestein BL, Bredt DS (1998), J Neurochem 71:1846-1853; Tseng CY, Firestein BL (2011), J Neurosci 31:15468-15480*). Hippocampi were dissociated, and cells were plated on 6 well plate coated with poly-D-lysine at a density of 6×10^5 cells/well. Neurons were cultured in Neurobasal media supplemented with B27, penicillin, streptomycin, and GlutaMax (Invitrogen).

[0045] To test the neurite regeneration *in vitro*, the wound healing assay were processed, which was used for testing cell migration and neurite outgrowth in previous reports (*Loh SH, Francescut L, Lingor P, Bahr M, Nicotera P (2008), Cell Death Differ 15:283-298; Wu CL, Chou YH, Chan Tseng CY, Firestein BL (2011) J Neurosci 31:15468-15480g; YJ, Teng NY, Hsu HL, Chen L (2012) PLoS One 7:e34999*). The tests were separated into four groups: Group 1: immature neuron, post-treatment; Group 2: immature neuron, pre- treatment; Group 3: mature neuron, post-treatment; Group 4: mature neuron, pre- treatment. All the treatments were administrated for 24 h. Mature neuron is the culture neuron in D.I.V 17 to 21, which is fully matured and formed the synaptic connection with other cells. It represents the most population of cells in adult brain. Immature neuron indicates the culture neuron in D.I.V 10 to 12, which has developed neurites but no spine - mediated synaptic connection. It stands for potential neuronal progenitor cells in the specific area of brain, such as subventricular zone. In Groups 1 and 3, different concentration of recomGMI is treated along with scrapping wound, while Groups 2 and 4 groups are pre-treated with different concentration of recomGMI 48 h before wound is made. The wound is made by P1000 tips and defined as healing day 0.

[0046] The results show that 1 µg/ml recomGMI has the obvious effects on promoting neurite regeneration both in Groups 1 and 2 (Figure 1 and Figure 2). As shown in Figure 4A and Figure 4B, we measured the outgrowth of the neurite regeneration and the quantitation results suggest the average neurite distance reach 140% and 170% of the control respectively at Group 1 treated with recomGMI 0.1 µg/ml and recomGMI 1 µg/ml. The neurite in Group 2 also can

regenerate up to 160% at recomGMI 1 µg/ml. Hence, both pre-treatment and co-treatment of recomGMI could ameliorate neurite outgrowth after injury. However, comparing Groups 3 and 4 (Figure 3), in matured neurons, pre-treatment of recomGMI (<1 µg/ml) enhance the regeneration of neurite after injury but not in co-treated group (Figure 4C, data not shown in image).
5 Quantitation data suggest neurite outgrowth can reach 180% at Group 4 (Figure 4D). However, the higher dose of recomGMI (5 and 10 µg/ml) is toxic to both mature and immature neurons.

Example 2 Morris Water Maze Task Assay

[0047] The Morris water maze (MWM) is a test of spatial learning for rodents that relies on distal cues to navigate from start locations around the perimeter of an open swimming arena
10 to locate a submerged escape platform. The water maze method was performed as described in *D'Hooge, R; De Deyn, PP (August 2001), "Applications of the Morris water maze in the study of learning and memory". Brain Research. Brain Research Reviews 36 (1): 60–90* with modifications.

[0048] A plastic black circular pool 160 cm in diameter and 45 cm in height was filled
15 with water (25 +/- 2°C) to a depth of 27 cm. A circular platform (12 cm in diameter) was placed at a specific location from the edge of the pool and submerged 2-3 cm below the water surface. For spatial learning, animals were subjected to 4 trials per day; each trial was conducted for 1 minute. The training procedure lasted 4 days, and a total of 16 trials were given. For these trials, the rats were positioned at different starting points spaced equally around the perimeter of the
20 pool in random order. They had 60 s to find the hidden platform. If a rat could not find the platform, it was guided to the platform and was allowed to remain there for 20 s. The time each animal took to reach the platform was recorded as the escape latency. A probe trial of 60 s was given on day 5 to test their memory retention. The rats were placed in the pool with the platform removed, and the time they spent in quadrant 5 was recorded. Quadrant 5 is the target quadrant.
25 For the trained and swimming control experiments, rats in the trained group were subjected to the regular water maze learning procedure.

[0049] After the water maze training procedure, three groups of S. D. rats (pretreat groups) were orally administered with 0.33 µg/kg recomGMI (pretreat low dose), 3.3 µg/kg recomGMI (pretreat middle dose) and 33 µg/kg recomGMI (pretreat high dose), respectively for
30 one month. The three groups of rats were subjected to brain injury surgery. After the surgery, the rates were continuously administered with 0.33 µg/kg recomGMI, 3.3 µg/kg recomGMI and 33

µg/kg recomGMI, respectively for one month. At the first four days, the rats were subject to water maze training procedure for 5 days.

[0050] Other three groups of S. D. rats were directly subjected to brain injury surgery without administration of recomGMI. After the surgery, the three groups of rats were orally administered with 0.33 µg/kg recomGMI (post-treat low dose), 3.3 µg/kg recomGMI (post-treat middle dose) and 33 µg/kg recomGMI (post-treat high dose), respectively for one month. At the first four days, the rats were subject to water maze training procedure for 5 days.

[0051] After the conclusion of the administration, the six groups of rats were subjected to the water maze assay. As shown in Figure 5, the treatment efficacy in the pretreat groups exhibits a dose-dependent manner and the post-treat middle dose group exhibits an advantageous effect in comparison with the sham group.

Claims

What is claimed is:

1. Use of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof, for the manufacture of a medicament for promoting neurite outgrowth.

5 2. The use of Claim 1, wherein the immunomodulatory protein from *Ganoderma*, or a recombinant thereof can promote the outgrowth of axons and dendrites.

3. The use of Claim 1, wherein the immunomodulatory protein or a recombinant thereof is derived from *Ganoderma lucidum*, *Ganoderma tsugae*, *Ganoderma microsporum* or *Ganoderma sinensis* or a recombinant thereof.

10 4. The use of Claim 1, wherein the immunomodulatory protein is LZ-8 derived from *Ganoderma lucidum*, FIP-gts derived from *Ganoderma tsugae*, GMI derived from *Ganoderma microsporum*, or FIP-gja derived from *Ganoderma sinensis* or a recombinant thereof.

5. The use of Claim 1, wherein the immunomodulatory protein is derived from *Ganoderma microsporum* (GMI) or a recombinant thereof (reGMI).

15 6. The use of Claim 1, wherein the immunomodulatory protein has the amino acid sequence as shown in SEQ ID NO:1 and SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.

7. The use of Claim 1, the amount for promotion of neurite outgrowth ranges between 0.65 µg to 650 µg of the immunomodulatory protein per kg body weight.

20 8. The use of Claim 1, wherein the medicament is used in combination with an additional neurite outgrowth agent.

9. Use of an immunomodulatory protein derived from *Ganoderma*, or a recombinant or a composition thereof for the manufacture of a medicament for treating and/or preventing a neurological disorder.

25 10. The use of Claim 9, wherein the immunomodulatory protein or a recombinant thereof is derived from *Ganoderma lucidum*, *Ganoderma tsugae*, *Ganoderma microsporum* or *Ganoderma sinensis* or a recombinant thereof.

11. The use of Claim 9, wherein the immunomodulatory protein is LZ-8 derived from *Ganoderma lucidum*, FIP-gts derived from *Ganoderma tsugae*, GMI derived from *Ganoderma microsporum*, or FIP-gja derived from *Ganoderma sinensis* or a recombinant thereof.

30 12. The use of Claim 9, wherein the immunomodulatory protein is derived from *Ganoderma microsporum* (GMI) or a recombinant thereof (reGMI).

13. The use of Claim 9, wherein the immunomodulatory protein has the amino acid sequence as shown in SEQ ID NO:1 and SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:4.

14. The use of Claim 9, wherein the neurological disorder is (i) a neurodegenerative disease, (ii) a condition of the nervous system that are secondary to a disease, condition, or therapy having a primary effect outside of the nervous system, (iii) an injury to the nervous system caused by trauma, (iv) memory loss, or (v) a psychiatric disorder.

15. The use of Claim 9, wherein the neurological disorder is peripheral nerve damage caused by physical injury, ischemia, prolonged exposure to cold temperature, damage to the central nervous system, dementia, Alzheimer's disease, Huntington's disease or Parkinson's disease.

16. The use of Claim 15, wherein the central nervous system damage is stroke or intracranial hemorrhage.

17. The use of Claim 9, the amount for treatment and/or prevention a neurological disorder ranges from about 0.65 μg to about 650 μg of the immunomodulatory protein per kg body weight.

18. The use of Claim 9, wherein the medicament is used in combination with an additional neurite outgrowth agent.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 4




Fig. 5

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CN2015/092299

A. CLASSIFICATION OF SUBJECT MATTER A61K 38/16(2006.01)i; A61P 25/00(2006.01)i According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K; A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CNABS,CNKI,VEN,NCBI,ISI-WEB OF KNOWLEDGE:immunomodulatory protein,Ganoderma,neurite,neuron,axon,dendrite,outgrowth,neurological,LZ-8,GMI,FIP-gts				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	CN 103536901 A (ZHANG XITIAN ET AL.) 29 January 2014 (2014-01-29) See the whole document, especially claim 1 and embodiment 2	1-18		
X	CN 103463618 A (ZHANG XITIAN ET AL.) 25 December 2013 (2013-12-25) See the whole document, especially the abstract, claims 1-2 and embodiment 1	1-18		
<div style="display: flex; justify-content: space-between;"> <input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex. </div>				
* Special categories of cited documents: <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> “A” document defining the general state of the art which is not considered to be of particular relevance “E” earlier application or patent but published on or after the international filing date “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) “O” document referring to an oral disclosure, use, exhibition or other means “P” document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top;"> “T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention “X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone “Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art “&” document member of the same patent family </td> </tr> </table>			“A” document defining the general state of the art which is not considered to be of particular relevance “E” earlier application or patent but published on or after the international filing date “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) “O” document referring to an oral disclosure, use, exhibition or other means “P” document published prior to the international filing date but later than the priority date claimed	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention “X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone “Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art “&” document member of the same patent family
“A” document defining the general state of the art which is not considered to be of particular relevance “E” earlier application or patent but published on or after the international filing date “L” document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) “O” document referring to an oral disclosure, use, exhibition or other means “P” document published prior to the international filing date but later than the priority date claimed	“T” later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention “X” document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone “Y” document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art “&” document member of the same patent family			
Date of the actual completion of the international search 15 January 2016		Date of mailing of the international search report 27 January 2016		
Name and mailing address of the ISA/CN STATE INTELLECTUAL PROPERTY OFFICE OF THE P.R.CHINA 6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing 100088, China Facsimile No. (86-10)62019451		Authorized officer TIAN,Yuan Telephone No. (86-10)62411047		

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.

PCT/CN2015/092299

Patent document cited in search report			Publication date (day/month/year)	Patent family member(s)			Publication date (day/month/year)
CN	103536901	A	29 January 2014	WO	2015058536	A1	30 April 2015
CN	103463618	A	25 December 2013	CN	103463618	B	03 September 2014
				WO	2015032233	A1	12 March 2015